drugset / Trial / NCT04538313
A Clinical Study in Patients With High-risk Recurrent Primary Hepatocellular Carcinoma Using Autologous TILs
Phase 1/2
Unknown
40 enrolled
CAR-T (Shanghai) Cell Biotechnology Co., Ltd.
Eastern Hepatobiliary Surgery Hospital · collab
Non-randomizedSequentialSingle-blindTreatment
Summary
Early clinical trials on evaluating the tolerance, safety and efficacy of autologous TILs in high-risk recurrent primary hepatocellular carcinoma
Timeline
- Start
- 2020-08-26
- Primary completion
- 2022-10-31
- Completion
- 2022-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 1e+09 cells | Other |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 1e+10 cells | Other |